Dia­gnostics of SARS-CoV2 antibodies

The detec­tion of anti­bod­ies is of great import­ance dur­ing or after a sus­pec­ted infec­tion. This allows to check whether patients are immune to COVID-19. ISAR Bioscience is, there­fore, cooper­at­ing in a research net­work on par­tic­u­larly fast and reli­able detec­tion meth­ods of anti­bod­ies dir­ec­ted against Corona and other vir­uses. The Bav­arian Research Found­a­tion will fund the pro­ject “Research on rapid microar­ray anti­body tests for COVID-19 dif­fer­en­tial dia­gnosis (CoV­Rapid)” with about 650,000 euros.

In addi­tion to rapid determ­in­a­tion, high sens­it­iv­ity and spe­cificity are import­ant for anti­body tests. While con­ven­tional anti­body tests only detect a single virus pro­tein, the new mul­ti­plex anti­body test by ISAR Bioscience and its part­ners uses a whole set of recom­bin­ant anti­gens which allows for detec­tion of anti­bod­ies against vari­ous SARS-CoV2 mutants (alpha, beta, delta and cur­rently omic­ron), as well as “older” corona vir­uses and other virus spe­cies. An auto­mated micro-array test based on micro­fluidics eval­u­ates the anti­body pat­terns within 5 minutes, using just one drop of blood. This approach enables a dif­fer­en­tial ana­lysis of immunity.